DOCSLIB.ORG

IHES Prelimn.Fm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IHES Prelimn.Fm ICD-9-CM for Hospitals and Payers – Volumes 1, 2, & 3 201 Expert International Classification of Diseases 9th Revision Clinical Modification Sixth Edition Edited by: Anita C. Hart, RHIA, CCS, CCS-P Melinda S. Stegman, MBA, CCS Beth Ford, RHIT, CCS OptumInsight is committed to providing you with the ICD-9-CM code update information you need to code accurately and to be in compliance with HIPAA regulations. In case of adoption of additional ICD-9-CM code changes effective April 1, 201, OptumInsight will provide these code changes to you at no additional cost! Just check back at www.optumcoding.com/productalerts to review the latest information concerning any new code changes. Codes Valid October 1, 201, through September 30, 201 Index to Diseases Abnormal, abnormality, abnormalities Index A Ablutomania 300.3 Abnormal, abnormality, abnormalities — Abnormal, abnormality, abnormalities — Abnormal, abnormality, abnormalities — see also Anomaly — continued see also Anomaly — continued AAT (alpha-1 antitrypsin) deficiency 273.4 see also Anomaly erythrocytes — continued hemoglobin (see also Disease, hemoglobin) AAV (disease) (illness) (infection) — see Human acid-base balance 276.4 congenital, with perinatal jaundice 282.7 immunodeficiency virus (disease) (ill- fetus or newborn — see Distress, fetal 282.9 [774.0] trait — see Trait, hemoglobin, abnormal ness) (infection) adaptation curve, dark 368.63 Eustachian valve 746.9 hemorrhage, uterus — see Hemorrhage, Abactio — see Abortion, induced alveolar ridge 525.9 excitability under minor stress 301.9 uterus Abactus venter — see Abortion, induced amnion 658.9 S fat distribution 782.9 histology NEC 795.4 Abarognosis 781.99 affecting fetus or newborn 762.9 feces 787.7 increase Abasia (-astasia) 307.9 anatomical relationship NEC 759.9 fetal heart rate — see Distress, fetal in atactica 781.3 apertures, congenital, diaphragm 756.6 fetus NEC appetite 783.6 choreic 781.3 auditory perception NEC 388.40 affecting management of pregnancy — development 783.9 hysterical 300.11 autosomes NEC 758.5 see Pregnancy, management af- involuntary movement 781.0 paroxysmal trepidant 781.3 13 758.1 fected by, fetal jaw closure 524.51 spastic 781.3 18 758.2 causing disproportion 653.7 S karyotype 795.2 trembling 781.3 21 or 22 758.0 affecting fetus or newborn 763.1 knee jerk 796.1 trepidans 781.3 D1 758.1 causing obstructed labor 660.1 S labor NEC 661.9 S Abderhalden-Kaufmann-Lignac syndrome affecting fetus or newborn 763.1 affecting fetus or newborn 763.7 E3 758.2 (cystinosis) 270.0 findings without manifest disease — see laboratory findings — see Findings, abnor- G 758.0 Abdomen, abdominal — see also condition Findings, abnormal mal ballistocardiogram 794.39 accordion 306.4 fluid length, organ or site, congenital — see Dis- basal metabolic rate (BMR) 794.7 acute 789.0 S amniotic 792.3 tortion biosynthesis, testicular androgen 257.2 angina 557.1 cerebrospinal 792.0 liver function test 790.6 blood level (of) burst 868.00 peritoneal 792.9 loss of height 781.91 cobalt 790.6 convulsive equivalent (see also Epilepsy) pleural 792.9 loss of weight 783.21 copper 790.6 345.5 S synovial 792.9 lung shadow 793.1 iron 790.6 heart 746.87 vaginal 792.9 mammogram 793.80 lead 790.6 muscle deficiency syndrome 756.79 S calcification 793.89 lithium 790.6 forces of labor NEC 661.9 obstipum 756.79 calculus 793.89 magnesium 790.6 affecting fetus or newborn 763.7 Abdominalgia 789.0 S microcalcification 793.81 mineral 790.6 form, teeth 520.2 periodic 277.31 Mantoux test 795.5 zinc 790.6 function studies Abduction contracture, hip or other joint — membranes (fetal) blood pressure auditory 794.15 see Contraction, joint affecting fetus or newborn 762.9 elevated (without diagnosis of hyperten- bladder 794.9 Abercrombie’s syndrome (amyloid degener- complicating pregnancy 658.8 S sion) 796.2 brain 794.00 ation) 277.39 cardiovascular 794.30 menstruation — see Menstruation low (see also Hypotension) 458.9 AAT — Abnormal, abnormality, abnormalities Aberrant (congenital) — see also Malposition, metabolism (see also condition) 783.9 reading (incidental) (isolated) (non- endocrine NEC 794.6 congenital movement 781.0 specific) 796.3 kidney 794.4 adrenal gland 759.1 disorder NEC 333.90 blood sugar 790.29 liver 794.8 blood vessel NEC 747.60 sleep related, unspecified 780.58 bowel sounds 787.5 nervous system arteriovenous NEC 747.60 specified NEC 333.99 breathing behavior — see Respiration central 794.00 cerebrovascular 747.81 head 781.0 caloric test 794.19 peripheral 794.19 gastrointestinal 747.61 involuntary 781.0 cervix (acquired) NEC 622.9 oculomotor 794.14 lower limb 747.64 specified type NEC 333.99 congenital 752.40 pancreas 794.9 renal 747.62 placenta 794.9 muscle contraction, localized 728.85 in pregnancy or childbirth 654.6 S spinal 747.82 pulmonary 794.2 myoglobin (Aberdeen) (Annapolis) 289.9 causing obstructed labor 660.2 S upper limb 747.63 retina 794.11 narrowness, eyelid 743.62 affecting fetus or newborn 763.1 breast 757.6 special senses 794.19 optokinetic response 379.57 chemistry, blood NEC 790.6 endocrine gland NEC 759.2 spleen 794.9 organs or tissues of pelvis NEC chest sounds 786.7 gastrointestinal vessel (peripheral) 747.61 thyroid 794.5 in pregnancy or childbirth 654.9 S chorion 658.9 S hepatic duct 751.69 vestibular 794.16 affecting fetus or newborn 763.89 affecting fetus or newborn 762.9 lower limb vessel (peripheral) 747.64 gait 781.2 causing obstructed labor 660.2 S chromosomal NEC 758.89 pancreas 751.7 hysterical 300.11 affecting fetus or newborn 763.1 analysis, nonspecific result 795.2 parathyroid gland 759.2 gastrin secretion 251.5 origin — see Malposition, congenital autosomes (see also Abnormal, auto- peripheral vascular vessel NEC 747.60 globulin palmar creases 757.2 somes NEC) 758.5 pituitary gland (pharyngeal) 759.2 cortisol-binding 255.8 Papanicolaou (smear) fetal, (suspected) affecting management renal blood vessel 747.62 thyroid-binding 246.8 anus 796.70 of pregnancy 655.1 S sebaceous glands, mucous membrane, glucagon secretion 251.4 with sex 758.81 mouth 750.26 glucose 790.29 atypical squamous cells clinical findings NEC 796.4 spinal vessel 747.82 in pregnancy, childbirth, or puerperium cannot exclude high grade communication — see Fistula spleen 759.0 648.8 S squamous intraepithe- configuration of pupils 379.49 testis (descent) 752.51 fetus or newborn 775.0 lial lesion (ASC-H) coronary thymus gland 759.2 non-fasting 790.29 796.72 artery 746.85 thyroid gland 759.2 gravitational (G) forces or states 994.9 of undetermined significance vein 746.9 upper limb vessel (peripheral) 747.63 hair NEC 704.2 (ASC-US) 796.71 cortisol-binding globulin 255.8 Aberratio hard tissue formation in pulp 522.3 cytologic evidence of malignancy course, Eustachian tube 744.24 lactis 757.6 head movement 781.0 796.76 creatinine clearance 794.4 testis 752.51 heart high grade squamous intraepithe- dentofacial NEC 524.9 Aberration — see also Anomaly rate lial lesion (HGSIL) 796.74 functional 524.50 chromosome — see Anomaly, chromo- fetus, affecting liveborn infant low grade squamous intraepithe- specified type NEC 524.89 some(s) before the onset of labor 763.81 lial lesion (LGSIL) 796.73 development, developmental NEC 759.9 distantial 368.9 during labor 763.82 glandular 796.70 bone 756.9 mental (see also Disorder, mental, nonpsy- unspecified as to time of onset specified finding NEC 796.79 central nervous system 742.9 chotic) 300.9 763.83 cervix 795.00 direction, teeth 524.30 Abetalipoproteinemia 272.5 intrauterine with Dynia (see also Defect, coagulation) 286.9 Abionarce 780.79 before the onset of labor 763.81 atypical squamous cells Ebstein 746.2 Abiotrophy 799.89 during labor 763.82 cannot exclude high grade echocardiogram 793.2 Ablatio unspecified as to time of onset squamous intraepithe- echoencephalogram 794.01 placentae — see Placenta, ablatio 763.83 lial lesion (ASC-H) echogram NEC — see Findings, abnormal, retinae (see also Detachment, retina) 361.9 newborn 795.02 structure Ablation before the onset of labor 763.81 of undetermined significance electrocardiogram (ECG) (EKG) 794.31 pituitary (gland) (with hypofunction) 253.7 during labor 763.82 (ASC-US) 795.01 electroencephalogram (EEG) 794.02 placenta — see Placenta, ablatio unspecified as to time of onset cytologic evidence of malignancy electromyogram (EMG) 794.17 uterus 621.8 763.83 795.06 ocular 794.14 Ablepharia, ablepharon, ablephary 743.62 shadow 793.2 high grade squamous intraepithe- electro-oculogram (EOG) 794.12 Ablepsia — see Blindness sounds NEC 785.3 lial lesion (HGSIL) 795.04 Ablepsy — see Blindness electroretinogram (ERG) 794.11 erythrocytes 289.9 S Additional Digit Required — Refer to the Tabular List for Digit Selection 2 Subterms under main terms may continue to next column or page 2013 ICD-9-CM wx Revised Text l New Line s Revised Code Volume 2 — 1 ICD9 V1 Hospital book.book Page 179 Tuesday, Ju ne 29, 2010 3:46 PM Tabular List Diseases of the Digestive System 531–533.3 Diseases of the Dige Diseases Stomach b 532 Duodenal ulcer Esophagus 1 erosion (acute) of duodenum ulcer (peptic): duodenum Diaphragm postpyloric Cardiac portion Stomach Fundus Use additional E code to identify drug, if drug-induced Pylorus 2 peptic ulcer NOS (533.0-533.9) Greater curvature The following fifth-digit subclassification is for use with category 532: 0 without mention of obstruction Pancreas 1 with obstruction Sphincter stive System System stive of Oddi Pancreatic DEF: Ulcers in duodenum due to action of gastric acid and pepsin on mucosa Common duct decreasing resistance to ulcers.
Load more

Recommended publications
  • Café Au Lait Spots As a Marker of Neuropaediatric Diseases
    Mini Review Open Access J Neurol Neurosurg Volume 3 Issue 5 - May 2017 DOI: 10.19080/OAJNN.2017.03.555622 Copyright © All rights are reserved by Francisco Carratalá-Marco Café Au Lait Spots as a Marker of Neuropaediatric Diseases Francisco Carratalá-Marco1*, Rosa María Ruiz-Miralles2, Patricia Andreo-Lillo1, Julia Dolores Miralles-Botella3, Lorena Pastor-Ferrándiz1 and Mercedes Juste-Ruiz2 1Neuropaediatric Unit, University Hospital of San Juan de Alicante, Spain 2Paediatric Department, University Hospital of San Juan de Alicante, Spain 3Dermatology Department, University Hospital of San Juan de Alicante, Spain Submission: March 22, 2017; Published: May 10, 2017 *Corresponding author: Francisco Carratalá-Marco, Neuropaediatric Unit, University Hospital of San Juan de Alicante, Spain, Tel: ; Email: Abstract Introduction: want to know in which The measure,Café au lait the spots presence (CALS) of isolated are shown CALS in representsthe normal a population risk factor forwithout neurological pathological disease. significance, although they could also be criteria for some neurologic syndromes. Unspecific association with general neurologic illnesses has been less frequently described. We Patients and methods: We set up an observational transversal study of cases, patients admitted for neuropaediatric reasons (NPP; n=49) excluding all the patients suffering from neurologic illnesses associated to CALS, and controls, a hospital simultaneously admitted pediatric population for non-neurologic causes (CP; n=101) since October 2012 to January 2013. The data were collected from the clinical reports at admission, and then analyzed by SPSS 22.0 statistical package, and the Stat Calc module of EpiInfo 7.0, following the ethics current rules of the institution for observational studies.
    [Show full text]
  • Vantage Total Ankle Replacement
    Total Ankle Replacement Find out why the Exactech Ankle may be right for you. UNDERSTANDING ANKLE REPLACEMENT This brochure offers a brief overview of ankle anatomy, arthritis and ankle replacement. This information is for educational purposes only and is not intended to replace the expert guidance of your physician. Please direct any questions or concerns you may have to your doctor. 02 ANKLE ARTHRITIS YOUR ANKLE Your ankle is made up of a variety of bones, ligaments, tendons and cartilage that connect at the junction of your leg and foot. The joint works like a hinge and is responsible for moving your foot up and down. The tibia (shinbone), talus and fibula (smaller bone in the lower leg) are the bones that construct the ankle joint. Your ligaments border these bones on either side, holding them together to provide stability. Meanwhile the tendons connect the muscles to the bone and are responsible for the ankle and toe movements. Covering your bones is a smooth substance called cartilage, which acts as a cushion to reduce the friction between your bones as they move. If your cartilage wears down, arthritis can develop and cause loss of motion and pain. TIBIA FIBULA TALUS CALCANEUS METATARSAL V 03 ARTHRITIC ANKLE HEALTHY ANKLE Nearly half of individuals over the age of 60 have foot or ankle arthritis. 04 ARTHRITIS Nearly half of individuals over the age of 60 have foot or ankle arthritis that may not cause symptoms.1 However, for those suffering from ankle arthritis pain the most reported causes are:2 • Rheumatoid arthritis - It is an autoimmune disease that attacks multiple joints and typically starts in the hands and feet.
    [Show full text]
  • EFFECTIVE NEBRASKA DEPARTMENT of 01/01/2017 HEALTH and HUMAN SERVICES 173 NAC 1 I TITLE 173 COMMUNICABLE DISEASES CHAPTER 1
    EFFECTIVE NEBRASKA DEPARTMENT OF 01/01/2017 HEALTH AND HUMAN SERVICES 173 NAC 1 TITLE 173 COMMUNICABLE DISEASES CHAPTER 1 REPORTING AND CONTROL OF COMMUNICABLE DISEASES TABLE OF CONTENTS SECTION SUBJECT PAGE 1-001 SCOPE AND AUTHORITY 1 1-002 DEFINITIONS 1 1-003 WHO MUST REPORT 2 1-003.01 Healthcare Providers (Physicians and Hospitals) 2 1-003.01A Reporting by PA’s and APRN’s 2 1-003.01B Reporting by Laboratories in lieu of Physicians 3 1-003.01C Reporting by Healthcare Facilities in lieu of Physicians for 3 Healthcare Associated Infections (HAIs) 1-003.02 Laboratories 3 1-003.02A Electronic Ordering of Laboratory Tests 3 1-004 REPORTABLE DISEASES, POISONINGS, AND ORGANISMS: 3 LISTS AND FREQUENCY OF REPORTS 1-004.01 Immediate Reports 4 1-004.01A List of Diseases, Poisonings, and Organisms 4 1-004.01B Clusters, Outbreaks, or Unusual Events, Including Possible 5 Bioterroristic Attacks 1-004.02 Reports Within Seven Days – List of Reportable Diseases, 5 Poisonings, and Organisms 1-004.03 Reporting of Antimicrobial Susceptibility 8 1-004.04 New or Emerging Diseases and Other Syndromes and Exposures – 8 Reporting and Submissions 1-004.04A Criteria 8 1-004.04B Surveillance Mechanism 8 1-004.05 Sexually Transmitted Diseases 9 1-004.06 Healthcare Associated Infections 9 1-005 METHODS OF REPORTING 9 1-005.01 Health Care Providers 9 1-005.01A Immediate Reports of Diseases, Poisonings, and Organisms 9 1-005.01B Immediate Reports of Clusters, Outbreaks, or Unusual Events, 9 Including Possible Bioterroristic Attacks i EFFECTIVE NEBRASKA DEPARTMENT OF
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • Joint Replacement Surgery Table of Contents
    Everything You Want to Know About Joint Replacement Surgery Table of Contents Understanding Your Joints: PG.3 How, when and why joint pain occurs Diagnosing Joint Pain: PG.4 The most common conditions and injuries Exploring the Options: PG.5 A look at partial and total joint replacement Seeing What’s New: PG.6 Medical advances in joint replacement surgery Answering Your Questions: PG.7 A discussion with Dr. Donald Hohman, Joint Replacement Program Medical Director Learning More: PG.9 Connecting with Texas Health Center for Diagnostics and Surgery Getting Ready: PG.10 My questions about joint replacement surgery Texas Health Center for Diagnostics & Surgery is a joint venture owned by Texas Health Resources and physicians dedicated to the community and meets the definition under federal law of physician-owned hospital. Physicians on the medical staff practice independently and are not employees or agents of the hospital. PAGE 2 Understanding Your Joints: How, when and why joint pain occurs Healthy joints aren’t just necessary for performing the physical activities we enjoy. They are the mechanical instruments that make virtually every movement possible. When our joints begin to succumb to years of natural wear and tear or degenerative conditions like arthritis, even the most common movements — like walking or climbing stairs — can become painful. Left untreated, joint pain can be potentially debilitating, severely diminishing one’s quality of life. New hope for joint pain Here’s the good news: it is possible to significantly reduce joint pain. Medical advancements in joint surgery have come a long way, particularly partial and total joint replacement.
    [Show full text]
  • Eye Disease 1 Eye Disease
    Eye disease 1 Eye disease Eye disease Classification and external resources [1] MeSH D005128 This is a partial list of human eye diseases and disorders. The World Health Organisation publishes a classification of known diseases and injuries called the International Statistical Classification of Diseases and Related Health Problems or ICD-10. This list uses that classification. H00-H59 Diseases of the eye and adnexa H00-H06 Disorders of eyelid, lacrimal system and orbit • (H00.0) Hordeolum ("stye" or "sty") — a bacterial infection of sebaceous glands of eyelashes • (H00.1) Chalazion — a cyst in the eyelid (usually upper eyelid) • (H01.0) Blepharitis — inflammation of eyelids and eyelashes; characterized by white flaky skin near the eyelashes • (H02.0) Entropion and trichiasis • (H02.1) Ectropion • (H02.2) Lagophthalmos • (H02.3) Blepharochalasis • (H02.4) Ptosis • (H02.6) Xanthelasma of eyelid • (H03.0*) Parasitic infestation of eyelid in diseases classified elsewhere • Dermatitis of eyelid due to Demodex species ( B88.0+ ) • Parasitic infestation of eyelid in: • leishmaniasis ( B55.-+ ) • loiasis ( B74.3+ ) • onchocerciasis ( B73+ ) • phthiriasis ( B85.3+ ) • (H03.1*) Involvement of eyelid in other infectious diseases classified elsewhere • Involvement of eyelid in: • herpesviral (herpes simplex) infection ( B00.5+ ) • leprosy ( A30.-+ ) • molluscum contagiosum ( B08.1+ ) • tuberculosis ( A18.4+ ) • yaws ( A66.-+ ) • zoster ( B02.3+ ) • (H03.8*) Involvement of eyelid in other diseases classified elsewhere • Involvement of eyelid in impetigo
    [Show full text]
  • C Lif I I I I C Lif I I I I California Immunization Requirements
    ClifCaliforn ia IiiImmunization Requirements for School & Child Care Entry Jennifer Sterling San Diego Immunization Partnership www.sdiz.org CtCounty of San Diego, HlthHealth and Human SiServices Agency Immunization Partnership Training Objectives At the end of this training, you will be able to: • List the immunization requirements for child care entry. • Identify acceptable forms of personal immunization records. • Correctly complete the California School Immunization Record (CSIR)/Blue Card. • Create a management system for conditional entrants and exemptions. Why Do We Need Immunizations? • Protect children and families • Prevent illnesses which can cause death and disability • Protect the health of others in the community • Good Public Health Practice Spread of Disease read of Disease –– a a cough, cough, sneezesneeze, or handshake away, or handshake away Vaccine Preventable Diseases in San Diego County Pertussis (Whooping Cough) >604 cases so far in 2010! The worst epidemic in 55 years. • Adults spreading sickness to babies. Nine babies under 3 months of age have died in California this year. • To preven t the sprea d o f Per tuss is, ge t the TDAP vacci ne! Chickenpox • 2009: 69 cases in 10 school districts • 2010: 10 cases in 2 school districts Measles • 2010: Three measles cases in Carlsbad, nine children quarantined • Measles outbreak in San Diego during January and February 2008‐first measles outbreak since 1991! ‐12 cases in 2008 ‐71 peopl e quarantine d Polio is still epidemic in 4 countries! Pertussis – Nearly 50% of the time, infants are infected by their parents Prevention of Disease – SimpleSimple!! Immunizations help prevent the spread of communicable diseases. Cover mouth (w/arm) when coughing or sneezing.
    [Show full text]
  • European Conference on Rare Diseases
    EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia
    [Show full text]
  • Diseases Transmitted Through the Food Supply
    DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Diseases Transmitted through the Food Supply AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human ­ Services (HHS). ­ ACTION: Notice of annual update of list of infectious and communicable diseases that are ­ transmitted through handling the food supply and the methods by which such diseases are ­ transmitted. ­ SUMMARY: Section 103 (d) of the Americans with Disabilities Act of 1990, Public Law 101–336, ­ requires the Secretary to publish a list of infectious and communicable diseases that are ­ transmitted through handling the food supply and to review and update the list annually. The ­ Centers for Disease Control and Prevention (CDC) published a final list on August 16, 1991 (56 ­ FR40897) and updates on September 8, 1992 (57 FR 40917); January 13, 1994 (59 FR 1949); ­ August 15, 1996 (61 FR 42426); September 22, 1997 (62 FR 49518–9); September 15, 1998 (63 ­ FR 49359); September 21, 1999 (64 FR 51127); September 27, 2000 (65 FR 58088); September ­ 10, 2001 (66 FR 47030); September 27, 2002 (67 FR 61109); September 26, 2006 (71 FR 56152); ­ November 17, 2008 (73 FR 67871); and November 29, 2009 (74 FR 61151). The final list has ­ been reviewed in light of new information and has been revised as set forth below. ­ DATES: Effective Date: January 31, 2014. ­ FOR FURTHER INFORMATION CONTACT: ­ Dr. Art Liang, Division of Foodborne Waterborne and Environment Diseases, National Center for ­ Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), ­ 1600 Clifton Road, NE., Mailstop G–24, Atlanta, Georgia 30333.
    [Show full text]
  • Part 3: European Commission Activities in the Field of Rare Diseases
    2014 REPORT ON THE STATE OF THE ART OF RARE DISEASE ACTIVITIES IN EUROPE PART III: EUROPEAN COMMISSION ACTIVITIES IN THE FIELD OF RARE DISEASES This work was financed by the EUCERD Joint Action: Working for Rare Diseases N° 2011 22 01 2014 Report on the State of the Art of Rare Disease Activities in Europe – Part III: European Commission activities in the field of rare diseases This document has been produced by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD) Joint Action through the EUCERD Joint Action: Working for Rare Diseases (N° 2011 22 01, Coordinator: Kate Bushby, University of Newcastle, United Kingdom), within the European Union’s Second Programme of Community Action in the Field of Health. The European Union Committee of Experts on Rare Diseases (EUCERD) was established in 2009 and its mandate ended in 2013. It is replaced from 2014 by the Commission Expert Group on Rare Diseases. The EUCERD Joint Action continues to support the activities of the new Expert Group until 2015. More information on the activities of the former European Union Committee of Experts on Rare Diseases and the EUCERD Joint Action can be found at www.eucerd.eu. Disclaimer: The findings and conclusions in this report are those of the contributors and validating authorities, who are responsible for the contents; the findings and conclusions do not necessarily represent the views of the European Commission or national health authorities in Europe. Therefore, no statement in this report should be construed as an official position of the European Commission or a national health authority.
    [Show full text]
  • EPO Surgeryplus Plan Amendment
    AMENDMENT TO THE COLORADO EMPLOYER BENEFIT TRUST EPO MEDICAL BENEFIT PLAN AND SUMMARY PLAN DESCRIPTION, EFFECTIVE JANUARY 1, 2019 The CEBT EPO Medical Benefit Plan and Summary Plan Description, effective January 1, 2019 (the “Plan”), shall be amended effective July 1, 2019 to include SurgeryPlus Benefits as follows: 1. Medical Covered Expenses: SURGERYPLUS BENEFIT Charges for certain surgeries, procedures, and related travel expenses are payable as shown on the Schedule of Benefits. This plan will pay charges for surgeries, procedures, and related travel as approved by SurgeryPlus for one Episode of Care. The SurgeryPlus benefit terminates upon your discharge from the hospital, ambulatory surgical center, or other facility following the Episode of Care. Any services rendered after the termination of the Episode of Care are subject to the applicable rules of this plan. Travel benefits may be payable if you do not have access to SurgeryPlus surgeons. The travel benefits will be determined by SurgeryPlus based upon the procedure, provider, and geographic distance of the provider in relation to your residence. Travel benefits may also be provided for a companion if your procedure requires inpatient or overnight care. Travel arrangements must be made through your SurgeryPlus Care Advocate for benefits to be payable. Some examples of the surgeries and procedures available through SurgeryPlus, include, but are not limited to the following: Knee: Foot & Ankle: General Surgery: Knee Replacement Ankle Replacement Gallbladder Removal Knee Replacement
    [Show full text]
  • Microtubule Regulation in Cystic Fibrosis Pathophysiology
    MICROTUBULE REGULATION IN CYSTIC FIBROSIS PATHOPHYSIOLOGY By: SHARON MARIE RYMUT Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Dr. Thomas J Kelley Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY August 2015 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/ dissertation of Sharon Marie Rymut candidate for the Doctor of Philosophy degree* Dissertation Advisor: Thomas J Kelley Committee Chair: Paul N MacDonald Committee Member: Ruth E Siegel Committee Member: Craig A Hodges Committee Member: Danny Manor Committee Member: Rebecca J Darrah Date of Defense: April 29, 2015 * We also certify that written approval has been obtained for any proprietary material contained therein. ii Dedication There are five chapters in this dissertation. To Mom, Dad, Joe, Marie and Susan, I dedicate one chapter to each of you. You can fight about which chapter you want later. iii Table of Contents Table of Contents................................................................................................................iv List of Tables .................................................................................................................... vii List of Figures .................................................................................................................. viii Acknowledgements ............................................................................................................. x List of Abbreviations .......................................................................................................
    [Show full text]